As such, inhibition of DNMTs has been developed as a therapeutic for various neoplasia [73], with the US Food and Drug Administration (FDA) having approved the DNMT inhibitor decitabine for the treatment of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) [74]. This evidence concerns the gene DNMT1 and myelodysplastic syndrome.